SG11201810454YA - Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment - Google Patents
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatmentInfo
- Publication number
- SG11201810454YA SG11201810454YA SG11201810454YA SG11201810454YA SG11201810454YA SG 11201810454Y A SG11201810454Y A SG 11201810454YA SG 11201810454Y A SG11201810454Y A SG 11201810454YA SG 11201810454Y A SG11201810454Y A SG 11201810454YA SG 11201810454Y A SG11201810454Y A SG 11201810454YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- washington
- antibody
- lymphoma
- pct
- Prior art date
Links
- 206010025323 Lymphomas Diseases 0.000 title abstract 2
- 208000017604 Hodgkin disease Diseases 0.000 abstract 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 abstract 1
- 229960000455 brentuximab vedotin Drugs 0.000 abstract 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 abstract 1
- 229960003301 nivolumab Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229960002621 pembrolizumab Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662344866P | 2016-06-02 | 2016-06-02 | |
US201662382839P | 2016-09-02 | 2016-09-02 | |
PCT/US2017/035521 WO2017210473A1 (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810454YA true SG11201810454YA (en) | 2018-12-28 |
Family
ID=59067913
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202101062YA SG10202101062YA (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
SG11201810454YA SG11201810454YA (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202101062YA SG10202101062YA (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
Country Status (19)
Country | Link |
---|---|
US (2) | US11299543B2 (fi) |
EP (2) | EP3464368B1 (fi) |
JP (3) | JP2019517505A (fi) |
KR (2) | KR20190008962A (fi) |
CN (1) | CN109476752A (fi) |
AU (1) | AU2017274444A1 (fi) |
BR (1) | BR112018074619A2 (fi) |
CA (1) | CA3026246A1 (fi) |
DK (1) | DK3464368T3 (fi) |
ES (1) | ES2951650T3 (fi) |
FI (1) | FI3464368T3 (fi) |
HU (1) | HUE063911T2 (fi) |
IL (1) | IL263165A (fi) |
MX (2) | MX2018014610A (fi) |
PL (1) | PL3464368T3 (fi) |
PT (1) | PT3464368T (fi) |
SG (2) | SG10202101062YA (fi) |
SI (1) | SI3464368T1 (fi) |
WO (1) | WO2017210473A1 (fi) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
CA3026246A1 (en) | 2016-06-02 | 2017-12-07 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
US20200239585A1 (en) * | 2017-10-13 | 2020-07-30 | Seattle Genetics, Inc. | Modulating the immune response using antibody-drug conjugates |
AU2019207812A1 (en) * | 2018-01-12 | 2020-07-23 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
WO2020135559A1 (en) * | 2018-12-26 | 2020-07-02 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
MX2022003357A (es) | 2019-09-25 | 2022-05-03 | Seagen Inc | Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos. |
KR20220114002A (ko) | 2019-12-09 | 2022-08-17 | 씨젠 인크. | Liv1-adc 및 pd-1 길항제를 사용하는 병용 요법 |
CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
AU2021273256A1 (en) * | 2020-05-13 | 2022-12-15 | Seagen Inc. | Methods of treating cancer using a combination of anti-CD30 antibody-drug conjugates |
WO2022187078A1 (en) | 2021-03-01 | 2022-09-09 | Nantbio, Inc. | Anti-cd30 monoclonal antibodies and chimeric antigen receptors |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
EP2161336B2 (en) | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
CL2007003622A1 (es) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
CN102131828B (zh) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
SI3279215T1 (sl) | 2009-11-24 | 2020-07-31 | Medimmune Limited | Usmerjena vezavna sredstva proti B7-H1 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
AU2014214843A1 (en) * | 2013-02-07 | 2015-05-21 | Immunomedics, Inc. | Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
JP6360077B2 (ja) * | 2013-02-20 | 2018-07-18 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 末梢t細胞リンパ腫の処置における使用のためのkir3dl2に特異的に結合する化合物 |
EP3770176A1 (en) | 2013-05-02 | 2021-01-27 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
WO2015069703A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
US11083790B2 (en) | 2016-06-02 | 2021-08-10 | Bristol-Myers Squibb Company | Treatment of Hodgkin lymphoma using an anti-PD-1 antibody |
CA3026246A1 (en) | 2016-06-02 | 2017-12-07 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
-
2017
- 2017-06-01 CA CA3026246A patent/CA3026246A1/en active Pending
- 2017-06-01 JP JP2018563009A patent/JP2019517505A/ja active Pending
- 2017-06-01 DK DK17730629.7T patent/DK3464368T3/da active
- 2017-06-01 SI SI201731383T patent/SI3464368T1/sl unknown
- 2017-06-01 US US16/306,282 patent/US11299543B2/en active Active
- 2017-06-01 SG SG10202101062YA patent/SG10202101062YA/en unknown
- 2017-06-01 EP EP17730629.7A patent/EP3464368B1/en active Active
- 2017-06-01 PT PT177306297T patent/PT3464368T/pt unknown
- 2017-06-01 BR BR112018074619A patent/BR112018074619A2/pt unknown
- 2017-06-01 SG SG11201810454YA patent/SG11201810454YA/en unknown
- 2017-06-01 KR KR1020187037834A patent/KR20190008962A/ko not_active IP Right Cessation
- 2017-06-01 ES ES17730629T patent/ES2951650T3/es active Active
- 2017-06-01 KR KR1020237026623A patent/KR20230119265A/ko not_active Application Discontinuation
- 2017-06-01 AU AU2017274444A patent/AU2017274444A1/en active Pending
- 2017-06-01 PL PL17730629.7T patent/PL3464368T3/pl unknown
- 2017-06-01 FI FIEP17730629.7T patent/FI3464368T3/fi active
- 2017-06-01 MX MX2018014610A patent/MX2018014610A/es unknown
- 2017-06-01 WO PCT/US2017/035521 patent/WO2017210473A1/en unknown
- 2017-06-01 HU HUE17730629A patent/HUE063911T2/hu unknown
- 2017-06-01 EP EP23174305.5A patent/EP4248989A3/en active Pending
- 2017-06-01 CN CN201780048015.7A patent/CN109476752A/zh active Pending
-
2018
- 2018-11-21 IL IL263165A patent/IL263165A/en unknown
- 2018-11-27 MX MX2022003571A patent/MX2022003571A/es unknown
-
2022
- 2022-04-07 US US17/715,875 patent/US20220298243A1/en active Pending
- 2022-08-18 JP JP2022130733A patent/JP2022176973A/ja active Pending
-
2023
- 2023-10-11 JP JP2023176091A patent/JP2024020202A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SI3464368T1 (sl) | 2023-10-30 |
DK3464368T3 (da) | 2023-10-02 |
PT3464368T (pt) | 2023-08-17 |
JP2024020202A (ja) | 2024-02-14 |
EP4248989A2 (en) | 2023-09-27 |
AU2017274444A1 (en) | 2018-12-13 |
US11299543B2 (en) | 2022-04-12 |
BR112018074619A2 (pt) | 2019-03-06 |
EP3464368A1 (en) | 2019-04-10 |
HUE063911T2 (hu) | 2024-02-28 |
JP2022176973A (ja) | 2022-11-30 |
US20220298243A1 (en) | 2022-09-22 |
SG10202101062YA (en) | 2021-03-30 |
ES2951650T3 (es) | 2023-10-24 |
IL263165A (en) | 2018-12-31 |
KR20190008962A (ko) | 2019-01-25 |
JP2019517505A (ja) | 2019-06-24 |
EP3464368B1 (en) | 2023-06-28 |
PL3464368T3 (pl) | 2023-08-28 |
KR20230119265A (ko) | 2023-08-16 |
MX2022003571A (es) | 2022-04-25 |
MX2018014610A (es) | 2019-02-28 |
US20190218293A1 (en) | 2019-07-18 |
EP4248989A3 (en) | 2023-12-27 |
WO2017210473A1 (en) | 2017-12-07 |
FI3464368T3 (fi) | 2023-09-12 |
CN109476752A (zh) | 2019-03-15 |
CA3026246A1 (en) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810454YA (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201804934PA (en) | Novel Compounds | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201808306PA (en) | Treatment of cancer with tg02 | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
SG11201810192TA (en) | Antibacterial compositions | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201901203PA (en) | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201810786RA (en) | [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |